Wilms Tumor Clinical Trials

72 clinical trials for Wilms Tumor across international registries, including 15 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) — RECRUITING · PHASE1
• Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor — RECRUITING · PHASE1
• Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors — RECRUITING · PHASE1
• Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors — RECRUITING · PHASE1
• B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) — RECRUITING · PHASE1
• Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors — RECRUITING · PHASE2
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors — RECRUITING · PHASE1
• Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation — RECRUITING · PHASE2
• Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies — RECRUITING · PHASE1
• Pencil Beam Scanning in Patients With Renal Tumors — RECRUITING · PHASE1
• Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) — RECRUITING · PHASE1
• Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells — RECRUITING · PHASE1
• Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells — RECRUITING · PHASE1
• International PPB/DICER1 Registry — RECRUITING
• Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models — COMPLETED
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• MetroWILMS-1906: Phase 1-2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumor — TERMINATED · PHASE2
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Kidney Tumors in Younger Patients — COMPLETED
• B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults — ACTIVE_NOT_RECRUITING · PHASE1
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas — COMPLETED · PHASE1
• Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults — ACTIVE_NOT_RECRUITING · PHASE1
• Molecular-Guided Therapy for Childhood Cancer — COMPLETED · NA
• Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma — COMPLETED · PHASE1
• Nephrogreen. Appearances of Exvivo Renal Tumours Under Near-infrared — COMPLETED · NA
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors — COMPLETED · PHASE2
• A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors — WITHDRAWN · PHASE2
• MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors — COMPLETED · PHASE1
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) — TERMINATED · PHASE2
• Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma — COMPLETED
• Study of Wilms Tumors Among Patients of Shefa Al-Orman Children Cancer Hospital — OTHER
• Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors — COMPLETED · PHASE1
• A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors — TERMINATED · PHASE1
• Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome — COMPLETED
• Drug Sensitivity and Mutation Profiling — COMPLETED
• Impact of an Orthotic Intervention in Children With Peripheral Neuropathy — COMPLETED · NA
• Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors — COMPLETED · PHASE1
• Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children — OTHER

Refine this search